Erlotinib cost-effective option in EGFR-mutated NSCLC

Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news

Related Links:

Conclusion RASSF1A methylation in lung cancer tissue can serve as a prognostic factor of NSCLC. More studies are needed to uncover the underlying mechanisms. PMID: 30764677 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
In this study, we investigated the expression and functional role of lncRNA small nucleolar RNA host gene 20 (SNHG20) as well as its underlying mechanism in NSCLC. Our results showed that SNHG20 was significantly up-regulated in NSCLC tissues and cells. High SNHG20 expression was implicated with poor prognosis in NSCLC patients. Moreover, SNHG20 knockdown suppressed proliferation, migration and invasion, and induced apoptosis in NSCLC cells. Furthermore, SNHG20 could function as a competing endogenous RNA (ceRNA) to elevate ZEB2 and RUNX2 expression by sponging miR-154. Rescue assays revealed that miR-154 inhibition could ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 15 February 2019Source: Process BiochemistryAuthor(s): M. Anandan, G. Poorani, P. Boomi, K. Varunkumar, K. Anand, A. Anil Chuturgoon, M. Saravanan, H. Gurumallesh PrabuAbstractDistinct morphological silver nanoparticles were synthesized using Dodonaea viscosa leaves, extracted using different polar and non-polar solvents. Petroleum ether, methanol, acetone, acetonitrile and water were used for the extraction of active ingredients from the leaves of Dodonaea viscosa which attributed to obtaining nanoparticles with different physical, chemical, antibacterial and cytotoxic properties. The sy...
Source: Process Biochemistry - Category: Biochemistry Source Type: research
Cardamonin, a natural chalcone compound, has been reported to exert anticancer effects in several cancers. However, the specific pharmacological actions of cardamonin on human non-small-cell lung cancer (NSCLC) and the potential mechanisms still remain obscure. Here, we investigated the antineoplastic role of cardamonin in NSCLC both in vitro and in vivo. The proliferation of five NSCLC cell lines was inhibited in a dose-dependent and time-dependent manner with cardamonin treatment. In A549 and H460 cells, cardamonin induced apoptosis by activating caspase-3, upregulating Bax, and downregulating Bcl-2. In addition, cardamo...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
In this study, nm23-H1 was down regulated in epithelial-mesenchymal transition (EMT) and stemness enhancement under cobalt chloride (CoCl2)-induced hypoxia in NSCLC cells. Moreover, knocking down of nm23-H1 by shRNA apparently promoted hypoxia induced EMT and stemness, which was entirely suppressed via over expression of nm23-H1. Mechanistically, the Wnt/β-catenin signaling pathway was found to participate in the nm23-H1-mediated process. Besides, XAV939 prohibited cell EMT and stemness which could be impaired by knocking down of nm23-H1, while stable transfection of nm23-H1 attenuated hypoxia phonotype induced by lit...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
Condition:   Non Small Cell Lung Cancer Interventions:   Other: Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation;   Procedure: Surgery Sponsor:   Shanghai 10th People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Solid Tumors;   Lymphoma;   HER2 Positive;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal C ell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: M7824 Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Non-small Cell Lung Cancer Interventions:   Drug: M7824;   Drug: Placebo;   Drug: Durvalumab;   Drug: Etoposide;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Cisplatin;   Radiation: Intensity Modulated Radiation Therapy (IMRT) Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: M7824 Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Drugs & Pharmacology | Non-Small Cell Lung Cancer | Tarceva